Related Experiment Videos
[The effect of OK-432 on modifying a spontaneous lung metastasis from murine fibrosarcomas]
H Ito1, S Yamada, I Nishiguchi
1Dept. of Radiology, Keio Univ. School of Med.
Abstract:
The authors have investigated the effect of OK-432 on the spontaneous metastasis from a murine fibrosarcoma, either an NFSA or a SANH, that had been transplanted into the right thigh of C3H mice. When the NFSA or the SANH tumors grew to 7 mm in diameter, they were irradiated with a single dose of 30 Gy and 20 Gy, respectively. A local administration of OK-432 (2.5 KE) around each of the tumors was initiated immediately after irradiation and continued twice a week. It was found that regrowth in both tumors was not modified by the OK-432, though the mean number of metastatic lung nodules per mouse from either tumor was significantly decreased. The incidence of a lung metastasis also was reduced by the OK-432 but not significantly. Further, mice that had received a SANH tumor transplant developed a lymph node metastasis in the abdominal cavity that was depressed by the OK-432.
Insights
OK-432 immunotherapy significantly reduced lung metastasis in mice with fibrosarcoma tumors. This immunotherapy did not affect tumor regrowth but decreased the number of metastatic nodules.
Area of Science:
- Oncology
- Immunotherapy
- Cancer Metastasis
Context:
- Investigating spontaneous metastasis in murine fibrosarcoma models (NFSA and SANH) in C3H mice.
- Tumors were locally administered with OK-432 immunotherapy post-irradiation.
- Established tumor models with a 7 mm diameter were used for the study.
Purpose:
- To evaluate the efficacy of OK-432 in preventing or reducing spontaneous metastasis from murine fibrosarcoma.
- To determine the impact of OK-432 on tumor regrowth following irradiation.
- To assess the effect of OK-432 on both lung and lymph node metastasis.
Summary:
- OK-432 treatment did not alter the regrowth of NFSA or SANH fibrosarcoma tumors after irradiation.
- A significant decrease in the mean number of lung metastatic nodules per mouse was observed with OK-432 administration.
- While not statistically significant, OK-432 also reduced the incidence of lung metastasis and depressed abdominal lymph node metastasis in SANH tumor-bearing mice.
Impact:
- OK-432 demonstrates potential as an immunotherapeutic agent to inhibit cancer metastasis, specifically lung and lymph node involvement.
- The findings suggest that OK-432 can be a valuable adjunct therapy in managing fibrosarcoma, focusing on controlling metastatic spread.
- Further research into OK-432's mechanism in suppressing metastasis could lead to novel therapeutic strategies for cancer patients.